F&P myAirvo™ 2 
Humidified High Flow Therapy 

 

World leading respiratory technology

 

Enquire about evaluating myAirvo

 

Facebook LinkedIn YouTube Twitter

Expert videos

Optiflow/ myAirvo

Resources/downloads

Humidified High Flow Therapy

Humidified high flow therapy with myAirvo 2 delivers warmed and humidified air/oxygen mixtures to the patient through a comfortable interface. It is designed for use in the home and long-term care facilities.

 



NHF reduces exacerbations compared to usual care in COPD patients

 

~ Storgaard et al 2018
~ Nagata et al 2022​



NHF improves quality
of life compared to usual care in patients with stable COPD
 

 

~ Nagata et al 2018
~ Storgaard et al 2018



NHF reduces PCO2 compared to usual care in patients with stable COPD
 

 

~ Nagata et al 2018
~ Storgaard et al 2018

How does Optiflow work?


The mechanisms of action

With NHF therapy, you can independently titrate flow and FiO2 to match your patient’s needs. The mechanisms of action differ from those of conventional therapies, as do the resulting physiological effects and clinical outcomes.

Mechanisms of NHF therapy are:​ 

  • Airway hydration
  • Respiratory support (through the reduction of dead space
  • and delivery of a dynamic positive airway pressure)
  • Patient comfort
  • Supplemental oxygen (if required)

Note: the above mechanisms of action for nasal high flow apply to delivery through an Optiflow nasal cannula interface. The mechanisms of action differ when high flow is delivered through a tracheostomy or mask interface adapter
 

Optiflow High Flow airway hydration mechanism overview

Airway hydration
 
Optiflow High Flow deadspace mechanism overview
Respiratory support
 
Optiflow High Flow pressure mechanism overview
Dynamic Positive Airway Pressure
 

Usage

There is an increasing body of clinical literature which may provide guidance on the day-to-day application of humidified high flow.
 

Discover webinars and expert videos on Humidified High Flow therapy in the home

ERS International Congress 2022: Recent Trial Results for Nasal High Flow on COPD patients in the home

ERS International Congress 2022: Recent Trial Results for Nasal High Flow on COPD patients in the home

Speakers: Dr Gerard Criner and Dr Kazuma Nagata

Learn more about the key findings and clinical outcomes from the recent clinical research on the Humidified High Flow therapy for COPD patients in the home.
ERS Webinar 2021-Benefits of NHF for COPD at home

ERS International Congress 2021: The Benefits of Nasal High Flow therapy in COPD patients in the home

Speakers: Drs Kazuma Nagata, Gerard Criner and Ulla Moller Weinreich

Our speakers, whose experience spans three continents, talk about their research and how Nasal High Flow therapy can benefit COPD patients in the home in this webinar.
Nasal high flow at home for COPD patients

Nasal high flow at home for COPD patients: a new paradigm

Speakers: Line Hust Storgaard and Ulla Moller Weinreich

Join Line Storgaard and Dr Ulla Weinreich to learn more about the use of Nasal High Flow with myAirvo to treat long term COPD patients in the home setting.

Ulla and Line’s experience running a large randomized controlled trial on 200 patients is presented. In addition, a subsequent analysis on the hypercapnic cohort, a qualitative study, and an economic analysis is also being discussed.

We value your privacy. Our websites and applications use cookies to function properly and securely.

De-identified Information, as described in our Global Privacy Statement, may be collected and used to support the performance of these sites, and to provide you with a better user experience. Cookie information is not used to promote personalised content on our websites. To learn more about how we use cookies, including examples, go to our Global Privacy Statement.